<a href=GSK” height=”170″ src=”https://www.pharmaceutical-technology.com/wp-content/uploads/image-digitalinsightresearch/Archive/Main/GSK.jpg” style=”padding: 10px” width=”288″ />

GlaxoSmithKline (GSK) is seeking approval from the European Medicines Agency (EMA) for its eltrombopag (Revolade).

The company has submitted marketing authorisation application for eltrombopag, seeking an additional indication to treat paediatric patients (age one year and above) with chronic immune (idiopathic) thrombocytopenic purpura (ITP), who have had an insufficient response to corticosteroids or immunoglobulins.

According to GSK, the EMA submission was based on results from the Phase III PETIT2 study (TRA115450) and the Phase II PETIT study (TRA108062) in paediatric chronic ITP.

Trials included the registration of a new 25mg powder for oral suspension formulation for eltrombopag and a new 12.5mg tablet.

"Trials included the registration of a new 25mg powder for oral suspension formulation for eltrombopag and a new 12.5mg tablet."

Marketed as Promacta in the US and Revolade in the EU, eltrombopag has not yet received approval or is licensed in any part of the world to treat chronic ITP in the paediatric setting.

In December 2014, GSK submitted a supplemental new drug application (sNDA) to US Food and Drug Administration (FDA) for eltrombopag (Promacta), seeking additional approval to treat paediatric patients over the age of six with chronic immune ITP.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In November 2014, GSK submitted a marketing authorisation application to the EMA seeking an additional indication for eltrombopag to treat adult patients with severe aplastic anaemia (SAA) who had an insufficient response to immunosuppressive therapy (IST).

The application was submitted based on the results of a pivotal open-label Phase II study (ELT112523) and two supporting Phase II studies (ELT116826 and ELT116643) by the National Institute of Health, assessing eltrombopag in patients with SAA.

Image: GlaxoSmithKline headquarters in Brentford, London, England. Photo: courtesy of Maxwell Hamilton.